Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis

source extracted confidence: high 2026-04-09
#calcium #contraceptive-agents #estrogens #female #humans

Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis

Gonçalves et al., 2022 | Reprod Biomed Online | Meta Analysis

Citation

Gonçalves Caroline R, Vasconcellos Amanda S, ... Reis Fernando M. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Biomed Online. 2022-Jun;44(6):1143-1157. doi:10.1016/j.rbmo.2022.02.006

Abstract

The aim of this systematic review and meta-analysis was to evaluate the effectiveness of different hormone therapies, including hormonal contraceptives, in women with premature ovarian insufficiency (POI). Thirty reports of 28 studies were included, with a total of 4004 participants with POI from diverse aetiologies, of whom 3785 received hormone therapies and 219 received calcium supplementation, vitamin D, placebo or no treatment. Hormone therapy was superior to non-treatment, placebo, calcitriol or calcium in preserving bone mineral density (BMD) in women with POI. Hormone therapy was associated with up to 80% reduction in the prevalence of hot flushes and with stability or improvement in the quality of life scores. Hormone therapy induced significant increases in uterine volume and endometrial thickness in women with POI. The studies yielded convergent results and were of good quality, although some lacked blinding or had incomplete outcome data. Moderate to high quality evidence was found that hormone therapy with oestrogen and progesterone or progestin (including contraceptives) is beneficial to women with POI, not only to mitigate hypoestrogenic symptoms but also to preserve BMD and avoid uterine atrophy. More studies are needed to confirm the long-term safety of this therapy and to assess its possible impact on the risk of hard outcomes such as bone fractures and cardiovascular events.

Key Findings

More studies are needed to confirm the long-term safety of this therapy and to assess its possible impact on the risk of hard outcomes such as bone fractures and cardiovascular events.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 4004
Age Range See abstract
Condition See abstract

MeSH Terms

  • Calcium
  • Contraceptive Agents
  • Estrogens
  • Female
  • Humans
  • Menopause, Premature
  • Primary Ovarian Insufficiency
  • Quality of Life

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Systematic Review
  • Vertical: calcium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09